Terms: = Liver cancer AND TOP2A, TOP2, TP2A AND Prognosis
41 results:
1. Immunotherapy and drug sensitivity predictive roles of a novel prognostic model in hepatocellular carcinoma.
Gao X; Ren X; Wang F; Ren X; Liu M; Cui G; Liu X
Sci Rep; 2024 Apr; 14(1):9509. PubMed ID: 38664521
[TBL] [Abstract] [Full Text] [Related]
2. Macroscopic inhibition of DNA damage repair pathways by targeting AP-2α with LEI110 eradicates hepatocellular carcinoma.
Wang C; Zhao Z; Zhao Y; Zhao J; Xia L; Xia Q
Commun Biol; 2024 Mar; 7(1):342. PubMed ID: 38503825
[TBL] [Abstract] [Full Text] [Related]
3. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating top2a.
Wang K; Jiang X; Jiang Y; Liu J; Du Y; Zhang Z; Li Y; Zhao X; Li J; Zhang R
J Exp Clin Cancer Res; 2023 Nov; 42(1):320. PubMed ID: 38008711
[TBL] [Abstract] [Full Text] [Related]
4. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.
Feng J; Wei X; Liu Y; Zhang Y; Li G; Xu Y; Zhou P; Zhang J; Han X; Zhang C; Zhang Y; Wang G
Aging (Albany NY); 2023 Nov; 15(22):13010-13040. PubMed ID: 37980167
[TBL] [Abstract] [Full Text] [Related]
5. [Screening and validation of pivotal genes in hepatitis B virus-associated hepatocellular carcinoma].
Wu YJ; Liu S; Tian YQ; Fan ZJ; Zhang L; Liu SY
Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):869-876. PubMed ID: 37723070
[No Abstract] [Full Text] [Related]
6. Based on network pharmacology and experiments to explore the underlying mechanism of Mahonia bealei (Fortune) Carrière for treating alcoholic hepatocellular carcinoma.
Zhang N; Zhu Y; Zhang X; Yang K; Yang X; An M; Tian C; Li J
J Ethnopharmacol; 2024 Jan; 318(Pt A):116919. PubMed ID: 37453621
[TBL] [Abstract] [Full Text] [Related]
7. Identification of ferroptosis and drug resistance related hub genes to predict the prognosis in Hepatocellular Carcinoma.
Li C; Cui X; Li Y; Guo D; He S
Sci Rep; 2023 May; 13(1):8681. PubMed ID: 37248280
[TBL] [Abstract] [Full Text] [Related]
8. CD69 serves as a potential diagnostic and prognostic biomarker for hepatocellular carcinoma.
Tang K; Li X; Mo J; Chen Y; Huang C; Li T; Luo T; Zhong Z; Jiang Y; Yang D; Mo W
Sci Rep; 2023 May; 13(1):7452. PubMed ID: 37156819
[TBL] [Abstract] [Full Text] [Related]
9. HBV-infected hepatocellular carcinoma can be robustly classified into three clinically relevant subgroups by a novel analytical protocol.
Cheng Z; Li L; Zhang Y; Ren Y; Gu J; Wang X; Zhao H; Lu H
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36736372
[TBL] [Abstract] [Full Text] [Related]
10. Significance of Identifying Key Genes Involved in HBV-Related Hepatocellular Carcinoma for Primary Care Surveillance of Patients with Cirrhosis.
Li Y; Li J; He T; Song Y; Wu J; Wang B
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553600
[TBL] [Abstract] [Full Text] [Related]
11. [Bioinformatics analysis of core differentially expressed genes in hepatitis B virus-related hepatocellular carcinoma].
Yu Y; Cheng J; Mei CZ; Dai YZ
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2022 Nov; 34(5):507-513. PubMed ID: 36464255
[TBL] [Abstract] [Full Text] [Related]
12. Custom gene expression panel for evaluation of potential molecular markers in hepatocellular carcinoma.
Pallerla SR; Hoan NX; Rachakonda S; Meyer CG; Van Tong H; Toan NL; Linh LTK; Giang DP; Kremsner PG; Bang MH; Song LH; Velavan TP
BMC Med Genomics; 2022 Nov; 15(1):235. PubMed ID: 36345011
[TBL] [Abstract] [Full Text] [Related]
13. Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy.
Hu Y; Tang C; Zhu W; Ye H; Lin Y; Wang R; Zhou T; Wen S; Yang J; Fang C
Comput Biol Med; 2022 Sep; 148():105896. PubMed ID: 35868048
[TBL] [Abstract] [Full Text] [Related]
14. Oncogenic role and potential regulatory mechanism of topoisomerase IIα in a pan-cancer analysis.
Wang X; Wang J; Lyu L; Gao X; Cai Y; Tang B
Sci Rep; 2022 Jul; 12(1):11161. PubMed ID: 35778520
[TBL] [Abstract] [Full Text] [Related]
15. Integrated Bioinformatics Analysis for the Screening of Hub Genes and Therapeutic Drugs in Hepatocellular Carcinoma.
Su Q; Li W; Zhang X; Wu R; Zheng K; Zhou T; Dong Y; He Y; Wang D; Ran J
Curr Pharm Biotechnol; 2023; 24(8):1035-1058. PubMed ID: 35762549
[TBL] [Abstract] [Full Text] [Related]
16. Identification of novel biomarkers in prostate cancer diagnosis and prognosis.
Li W; Xu W; Sun K; Wang F; Wong TW; Kong AN
J Biochem Mol Toxicol; 2022 Sep; 36(9):e23137. PubMed ID: 35686336
[TBL] [Abstract] [Full Text] [Related]
17. A Risk Model Developed Based on Necroptosis Predicts Overall Survival for Hepatocellular Carcinoma and Identification of Possible Therapeutic Drugs.
Li Z; Fang J; Chen S; Liu H; Zhou J; Huang J; Liu S; Peng Y
Front Immunol; 2022; 13():870264. PubMed ID: 35422802
[TBL] [Abstract] [Full Text] [Related]
18. An Immune-Related Gene Signature Predicting prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Zhang F; Cai J; Hu K; Liu W; Lu S; Tang B; Li M; Wu W; Ren Z; Yin X
Comb Chem High Throughput Screen; 2022; 25(13):2203-2216. PubMed ID: 35249477
[TBL] [Abstract] [Full Text] [Related]
19. [Correlation between TOPA2A gene expression and the number of CD4
Lu X; Yu P; Tao H; Chen Y; Lu J
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Jan; 38(1):24-31. PubMed ID: 35078572
[TBL] [Abstract] [Full Text] [Related]
20. Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis.
Yang T; Chen Y; Xu J; Li J; Liu H; Liu N
BMC Complement Med Ther; 2022 Jan; 22(1):21. PubMed ID: 35078445
[TBL] [Abstract] [Full Text] [Related]
[Next]
